BNP Screening for PAH in Scleroderma PDF Print E-mail
Tuesday, 24 July 2012 19:41
An elevated level of N-terminal pro-brain natriuretic peptide (NT-proBNP) has a high sensitivity and specificity for pulmonary arterial hypertension in patients with systemic sclerosis (SSc-PAH), Australian rheumatologists and cardiologists have suggested.

They investigated a total of 94 patients with systemic sclerosis in four groups: one with SSc-PAH confirmed by right heart catheterisation, another considered at high risk because of findings on trans-thoracic echocardiography, a group with interstitial lung disease, and a group with no cardiopulmonary complications.

“NT-proBNP was highest in the PAH group compared with the other groups, and higher in the risk group compared with controls,” they said.

The marker was positively correlated with systolic and mean pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.

Further analysis defined thresholds for NT-proBNP and/or results on carbon monoxide pulmonary diffusion tests that should prompt investigation for possible PAH, for example with echocardiography, high-resolution CT, 6-minute walk test, and definitive right heart catheterisation when indicated.

PAH accounted for about 30% of deaths related to systemic sclerosis, the researchers said. In its earliest stages, patients were often asymptomatic or minimally symptomatic but early detection and treatment could delay progression and improve survival.

Annual echocardiography was recommended to screen for early PAH, but this strategy had limitations including technical challenges, insufficient reliability in the presence of coexisting lung disease, poor acoustic windows in some patients, the need for expertise, and issues of cost and resource allocation.

NT-proBNP was released by cardiac myocytes in response to increased ventricular wall stress. The blood test was now widely available given its importance in the diagnosis, prognosis and risk stratification of congestive cardiac failure, they said.

Source: James, T. (2012), "BNP screening for pulmonary arterial hypertension in systemic sclerosis"; Rheumatology Update; original article can be viewed here.

 
More articles :

» arGentis Continues To Expand

But arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the - the terms of which, were not disclosed. The treatment was developed at the University of Tennessee Health...

» Scleroderma Study Results Comes As Bitter Disappointment

Elizabeth Lombard has .The disease, which has no cure, has long confounded South Boston, where a cluster of longtime residents from the City Point section - most of them middle-aged women - were falling ill with it. The residents, who lived near a...

» Finding Reliable Health Information Online

As Internet users quickly discover, an enormous amount of health information is available online. Finding accurate and reliable information on genetic and rare diseases among the millions of online sources is a difficult task for almost everyone. We...

» Free the Free Radicals

We’re all used to hearing that everything we once thought was good for us is not. But even within that framework, the latest science about , free radicals and exercise is telling. As many of us have heard, free radicals are molecules created by...

» Juvenile Scleroderma Progression Similar To Adult Onset

The pattern and course of disease in patients who develop systemic sclerosis in childhood or adolescence is similar to that in patients who develop the disease as adults, data from Europe has shown.There were 60 patients among 5,000 included in the...

» Cancer Drug Shows Promise For Treating Scleroderma

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with , according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold...